The development of trastuzumab, a humanized monoclonal antibody that binds to the HER2 extracellular domain, has transformed the treatment of HER2-positive breast cancers (2) and improved clinical responses (2–4) and disease free survival (5). The gene discussed is ERBB2; the disease is breast carcinoma.